CAR-T cell therapy represents a breakthrough immunotherapy for relapsed and refractory blood cancers, now accessible in India at a fraction of global costs, making advanced cancer treatment available to patients who previously had limited options. TL;DR India's CAR-T cell therapy costs Rs 30-40 lakhs compared to Rs 3-4 crore internationally, representing 90% savings for patients [2] Indigenous therapies like NexCAR19 have demonstrated a 70% overall response rate in clinical t